 Connection
Daniel Sherbenou to Immunotherapy, Adoptive
This is a "connection" page, showing publications Daniel Sherbenou has written about Immunotherapy, Adoptive.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.925 |
|
|
|
-
Keller AL, Dennis KA, Ohlstrom DJ, Parzych SE, Walker ZJ, Novak AJ, Pham-Danis C, Medha TN, Rahkola JT, Boorgula MP, Kohler ME, Sherbenou DW. Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype. Cancer Immunol Res. 2026 Aug 04; 14(8):1307-1321.
Score: 0.744
-
Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ. Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium. Blood Cancer J. 2026 03 20; 16(1).
Score: 0.181
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|